Sara Van Driest

Anti-nausea drug response in children

Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.

Van Driest to lead All of Us pediatric research

Vanderbilt’s Sara Van Driest, MD, PhD, has assumed a new post as the first-ever director of pediatrics for the National Institutes of Health’s All of Us Research Program, which aims to accelerate the prevention and treatment of illness through precision medicine.

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Two VUMC papers named among genomic medicine’s top 10

Vanderbilt researchers wrote two of the “top 10” papers representing key advances in genomic medicine published between September 2020 and August 2021.

Grant creates center for maternal, pediatric precision therapeutics

Vanderbilt University Medical Center has been awarded a five-year, $6 million grant from the National Institutes of Health to serve as a center of excellence for Maternal and Pediatric Precision in Therapeutics.

From left, Dan Roden, MD, Ayesha Muhammad, Jonathan Mosley, MD, PhD, and Sara Van Driest, MD, PhD, found that a genome-wide approach can improve the prediction of drug responses.

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

1 2